Compass Biotechnologies Shareholder Update
Compass Biotechnologies Inc. (PINKSHEETS: COBI) is pleased to update its shareholders and announce its intentions to move forward with its plans to refocus the core business model and direction of the company.
Under the direction of company's newly appointed CEO, Bradley Wilson, Compass has shifted its focus to the global Exploration and Energy sector, focusing on international properties that have established business assets, cash flow and sustainable operations to refocus our acquisition strategy.
Compass has hereby revoked the stock purchase agreement with 1WorldDirect US Inc., due to non performance. In light of the events, the Board is pleased to appoint Mr. Wilson, as he has established several relationships to acquire properties to expand the asset base of Compass. In addition, Compass will begin to divest itself of its biotech licenses, patents and assets over the next quarter to solely focus on energy and exploration.
Additional details will be forthcoming over the next several weeks and our new website will be available at: www.compassholdingcorp.com. The company will continue updating OTC Markets along with its website as a continued source of information to keep our shareholders up to date on all progress and developments.
ABOUT COMPASS BIOTECHNOLOGIES INC.
Compass Biotechnologies Inc. is a diversified holding company that leverages emerging technologies in strategic alliances in the biotechnology market and is also transitioning its business model to the global exploration and resource sector.